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10 to 12 percent of all hip arthroplasties are performed because
of ONFH. However, outcome is reported to be poorer after
hip replacement for ONFM than for osteoarthritis (OA), due to
migration of the femoral component and aseptic stem loosening.
The reason for this higher failure rate in patients with ONFH is
unknown; a potential cause discussed is abnormal cancellous
bone in the femoral head, the intertrochanteric region and the
proximal femoral shaft. Bone metabolism und remodelling in
patients with ONFH is supposed to be widely regulated by
cytokines, bone morphogenetic factors and angiogenetic factors.
We hypothesize that differences in gene and protein expression
exist between patients with ONFH and primary OA not only in
the femoral head-neck region but also the intertrochanteric area
and the proximal femoral shaft.
Therefore, the objective of our study was to assess and compare
gene and protein expression of different growth and angiogenetic
factors in patients with advanced ONFH and primary OA of the
hip joint and their influence on bone quality.
Methods: From patients receiving cement less total hip replace-
ment the femoral head was removed in total, sectioned in the
coronal plane at 0.5 cm intervals and a bone sample (1cm3)
was gained from the center of the osteonecrotic lesion. Before
reaming the femoral canal, further samples of cancellous bone
(0.5 cm3) were taken from the following four areas: Base of the
femoral neck, the lesser and greater trochanter and the medullary
canal approximately 4 cm below the lesser trochanter and saved
for gene and protein analysis.
Results: Gene expression of BMP2 and -7, FGF2, TGFβ1, VEGF
and Cbfa1 is significantly higher in patients with ONFH compared
to patients with OA. Elevated gene expression for BMP-2 and
VEGF was found in the femoral head-neck region and the prox-
imal femur while FGF2, BMP-7, TGFβ1 and Cbfa1 revealed a
higher gene expression in the femoral head-neck region only.
In order to assess structural differences in the bone matrix, im-
munohistological analysis was performed for osteocalcin as a
bone specific component. A differential collagen profile provides
information about the composition of tensile providing elements
in patients with ONFH compared to OA.
Conclusions: We documented differences in gene expression
between patients with ONFH and OA as well as differences in
gene expression between different regions of the femoral head.
Analysis of distribution and composition of structural components
together with the gene expression profile will enable us to gain
a better understanding of the patho-physiological mechanism
involved in ONFH. These results may contribute in development
of novel therapeutic approaches to treat ONFH and in improving
the survivorship of total hip replacements in patients with ONFH.
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Purpose: Homodimeric bone morphogenetic protein-2 (BMP-2)
belongs to the transforming growth factor-β superfamily that plays
an important role during bone regeneration and repair as well
as during various stages of embryonic development. BMP-2 has
been produced from mammalian cell cultures but with low yields.
Biologically active BMP-2 has been produced from Escherichia
coli through in vitro refolding of inclusion bodies, but the refolding
procedure is complicated and the overall yield is low or the
refolding buffer contains expensive reagents. Our goal was to
develop a new, simple and inexpensive method to improve the
production of biologically active BMP-2.
Methods: A 345-bp gene that encodes hBMP-2 has been syn-
thesized. The design of the synthetic hBMP-2 gene was based
on the amino-acid sequence of hBMP-2 and used the following
strategy. The hBMP-2 gene was assembled from two gene seg-
ments that were initially cloned into pUC18. A DNA sequence
containing 11 restriction sites located approximately every 30 bp
throughout the entire length of the coding region was selected
from the large number of possibilities. Only those sites that are
not located in pUC18 (except in the polylinker region) were in-
cluded and the gene was flanked by unique EcoRI and HindIII
sites. The codon usage of the resulting BMP-2 gene was modi-
fied to include those triplets that are utilized in highly expressed
E. coli genes while retaining the largest possible number of
unique restriction sites. In some cases, suboptional codons were
used either to allow the inclusion of unique restriction sites or
to preclude redundant sites. A ribosome binding site was added
10 bases upstream of the coding region to direct the initiation
of translation in E. coli. The sequence adjacent to the ribosome
binding site included an A at position -3 relative to the ATG, and
the spacer region (-1 to -9) was made A + T rich to reduce po-
tential mRNA secondary structure in the vicinity of the translation
start site. Addition of a ribosome binding site made the synthetic
hBMP-2 gene portable to any of a number of commonly available
plasmid vectors that carry inducible E. coli promoters.
Results: The BMP-2 gene was subcloned into pCold I vector
and high level expression of the synthetic hBMP-2 gene was
achieved in Origami B(DE3) after incubation at 16°C for 16
h. SDS/PAGE analysis and Western blot of crude cell extracts
showed high level expression of hBMP-2 at a position of 12-kDa
protein. The 12-kDa protein were absent in extracts from Origami
B(DE3) transformed with pCold I vector only. hBMP-2 was homo-
geneously purified using heparin-Sepharose column and FPLC
Resource-Q column. N-terminal sequence analysis of the first
8 amino acids, M-Q-A-K-H-K-Q-R, was in good agreement with
published sequence of authentic hBMP-2. The purified rhBMP-2
showed a molecular size of 12-kDa and 24-kDa for monomer
and dimer, respectively, as determined by SDS-PAGE and HPLC
gel filtration. hBMP-2 dimer (24 kDa) possessed similar level of
activity as hBMP-2 from CHO cells, whereas hBMP-2 monomer
(12 kDa) did not show any biological activity.
Conclusions: A gene that encodes mature hBMP-2 has been
synthesized and successfully expressed as a biologically active
soluble protein in E. coli. Our results showed a new, simple and
inexpensive method to improve the over-production of biologically
active hBMP-2. Supported by the Korea Health R&D Project from
the Ministry of Health & Welfare (A060406) to S.-W. Cho.
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Purpose: Our group has been applying autologous bone marrow
transplantation as novel therapic approach for aseptic necrosis
of the femoral head. Bone regeneration is expected by effects
of transplanting concentrated "buffy coat" that contain not only
multipotent stem like cells but also several angiogenic and os-
teogenic growth factors such as FGF-2, TGFβ, PDGF, VEGF,
IGF-I. But there are no previous reports about the concentration
of angiogenic and osteogenic growth factors in bone marrow
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blood and buffy coat. The purpose of this study is to compare
the concentration of angiogenic and osteogenic growth factors
in bone marrow blood, peripheral blood and buffy coat in os-
teonecrosis of the femoral head patients.
Methods: Autologous bone marrow transplantation was applied
to thirty patients, aged 23 to 63 (mean 43.2 years old) with
aseptic osteonecrosis of the femoral head (idiopathic, alcoholic,
steroid induced, post traumatic). Peripheral blood and bone mar-
row blood taken from iliac crest were transferred to the centrifu-
gation tubes. After clotting, the blood samples were centrifuged
at 2000 rpm for 10 min. The supernatants were used as the
serum samples. Buffy coat was obtained with centrifugation of
bone marrow blood taken with anticoagulant solution (citric acid,
sodium citrate, and dextrose) and transplanted to the femoral
head. The concentrations of FGF-2, TGF-β1, PDGF, VEGF and
IGF-I were measured by using enzyme-linked immunosorbent
assay with the serum of peripheral blood and bone marrow
blood, and with the plasma fraction of concentrated buffy coat.
The statistical differences were determined by two-sided paired t
test. Difference with p<0.01 was considered significant.
Results: Serum growth factors levels in bone marrow and periph-
eral blood:
FGF-2 in bone marrow blood was significantly higher than in
peripheral blood. TGF-β1 and IGF-I in peripheral blood were sig-
nificantly higher than bone marrow blood. PDGF and VEGF are
higher in peripheral blood without significant difference compared
to that of bone marrow blood.Concentration of growth factors in
bone marrow and transplanted buffy coat:
Fig. 1. *p < 0.01; **p < 0.005; ***p < 0.001.
P122
Buffy coat was also containing significantly higher concentration
of IGF-I and VEGF than serum of bone marrow blood. PDGF and
TGF-β1 were higher in buffy coat without significant difference.
Conclusions: These growth factors are generated by various
precursors and matured cells, and systemically transported with
the cells, platelets and plasma. Therefore there are level dif-
ferences peculiar to each growth factor in peripheral and bone
marrow blood. As a result of these experiments, FGF-2 was
abundant in bone marrow blood. Concentrated bone marrow
contained higher concentrations of angiogenic and osteogenic
growth factors. These results, with clinical samples might pro-
vide useful evidence for the regenerative medicines which use
autologous bone marrow and growth factors.
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Purpose: This investigation examined if bone hypertrophic adap-
tation in end-stage Osteoarthritis (OA) was associated with
